Levofloxacina Krka (Levofloxacin)

Levofloxacina Krka is a broad‑spectrum fluoroquinolone used to manage bacterial infections across several organ systems.

• Urinary tract infections: eradicates susceptible uropathogens, relieving dysuria and preventing recurrence.
• Respiratory tract infections: treats community‑acquired pneumonia and bronchitis caused by susceptible bacteria.
• Skin and soft tissue infections: resolves cellulitis, abscesses, and wound infections.
• Prostatitis: eliminates bacterial involvement in chronic bacterial prostatitis.
• Complicated intra‑abdominal infections: provides coverage for mixed aerobic and anaerobic organisms.

• Levofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By stabilizing the enzyme‑DNA complex, it prevents the resealing of DNA strands, leading to bacterial cell death. This bactericidal action is effective against a wide range of Gram‑negative and Gram‑positive organisms.

Levofloxacina Krka may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools, sometimes watery.
• Headache: transient cranial discomfort.
• Dizziness: sensation of light‑headedness.
• Photosensitivity: increased skin sensitivity to sunlight.
• Abdominal pain: cramping or discomfort.

Serious or Rare Side Effects

• Tendon rupture: especially Achilles tendon, often linked to sudden activity.
• QT interval prolongation: may precipitate cardiac arrhythmias.
• Severe allergic reactions: including anaphylaxis and Stevens‑Johnson syndrome.
• Clostridioides difficile infection: colitis due to gut flora disruption.
• Peripheral neuropathy: tingling or numbness in extremities.
• Hepatic toxicity: elevated liver enzymes or jaundice.

Before prescribing Levofloxacina Krka, clinicians should consider several safety aspects.

• Renal function: adjust dosing in patients with severe renal impairment.
• History of tendon disorders: avoid use in individuals with prior tendon injury.
• Cardiac risk: monitor QT interval in patients with known prolongation or on other QT‑prolonging drugs.
• Concomitant antacids or supplements: separate administration by at least two hours to ensure absorption.
• Pregnancy and lactation: reserve for situations where benefits outweigh potential risks.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Levofloxacina Krka can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

• Warfarin: may potentiate anticoagulant effect, increasing bleeding risk.
• Theophylline: levofloxacin can raise theophylline levels, leading to toxicity.
• Antacids or supplements containing aluminum, magnesium, calcium, or iron: significantly decrease levofloxacin absorption.

Moderate Interactions (Monitor Closely)

• Corticosteroids: combined use may increase risk of tendon rupture.
• Cyclosporine: levofloxacin may raise cyclosporine concentrations, necessitating therapeutic monitoring.